UK markets closed

Immunome, Inc. (IMNM)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
14.92-1.12 (-6.98%)
At close: 04:00PM EDT
14.92 0.00 (0.00%)
After hours: 07:32PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 894.74M
Enterprise value 586.65M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)22.79
Price/book (mrq)3.13
Enterprise value/revenue 46.26
Enterprise value/EBITDA -0.72

Trading information

Stock price history

Beta (5Y monthly) 1.85
52-week change 3162.68%
S&P500 52-week change 323.76%
52-week high 330.96
52-week low 35.26
50-day moving average 315.78
200-day moving average 313.97

Share statistics

Avg vol (3-month) 3776.43k
Avg vol (10-day) 3707.07k
Shares outstanding 559.97M
Implied shares outstanding 659.97M
Float 842.89M
% held by insiders 117.08%
% held by institutions 161.51%
Shares short (15 May 2024) 46.12M
Short ratio (15 May 2024) 46.94
Short % of float (15 May 2024) 410.80%
Short % of shares outstanding (15 May 2024) 410.21%
Shares short (prior month 15 Apr 2024) 43.75M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,977.16%

Management effectiveness

Return on assets (ttm)-15.16%
Return on equity (ttm)-154.98%

Income statement

Revenue (ttm)12.68M
Revenue per share (ttm)0.43
Quarterly revenue growth (yoy)-56.50%
Gross profit (ttm)N/A
EBITDA -44.08M
Net income avi to common (ttm)-232.03M
Diluted EPS (ttm)-17.58
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)309.71M
Total cash per share (mrq)5.16
Total debt (mrq)1.62M
Total debt/equity (mrq)0.57%
Current ratio (mrq)10.18
Book value per share (mrq)4.78

Cash flow statement

Operating cash flow (ttm)-42.91M
Levered free cash flow (ttm)-18.52M